Anthony Traurig, Author at CannIntelligence

Medical cannabis database

Written by Anthony Traurig || 8th October 2024 || Market data , Regulatory databases |

This medical cannabis database provides important details about the regulatory frameworks for medical cannabis in 21 of the most important markets globally, as well as market data on several global markets ...

US regulatory tracker: state regulation of delta-8 THC, July

Written by Anthony Traurig || 26th July 2024 || Regulatory databases |

This interactive tracker provides an overview of CannIntelligence's understanding of delta-8 THC regulation in each state including links to relevant bills and legislation ...

US regulatory tracker: enacted regulation of CBD, July

Written by Anthony Traurig || 26th July 2024 || Regulatory databases |

CannIntelligence's US enacted law regulatory tracker, updated quarterly, provides a deep analysis of each regulatory area. Within this interactive map gain insight into the enacted laws in 50 US states ...

Developments and trends in the global cannabis industry, Q2 2024

Written by Anthony Traurig || 25th July 2024 || Market reports , Regulatory reports |

CannIntelligence presents the latest regulatory and market developments and trends in the global cannabis industry in slide deck format. The slide deck covers the latest developments from the second quarter of 2024 ...

Regulatory tracker: HHC in Europe, June

Written by Anthony Traurig || 17th June 2024 || Regulatory databases |

The Europe HHC regulatory tracker offers an in-depth analysis of the regulations surrounding hexahydrocannabinol (HHC) in 30 European countries ...

Thailand: CBD and cannabis regulation, October 2023

Written by Anthony Traurig || 4th October 2023 || Regulatory reports |

This report offers detailed analysis of the current regulatory framework in place in Thailand for cannabis and cannabinoids, including CBD and hemp. It covers everything from cultivation and processing to finished products, extracts and import/export ...

US scheduling recommendation could bring big boost to cannabis industry

Written by Anthony Traurig || 1st September 2023 || News analysis |

The US Department of Health and Human Services recommendation to reschedule cannabis to a less restrictive schedule could be the boon that the besieged cannabis industry needs ...

US federal: CBD and cannabis regulation, August 2023

Written by Anthony Traurig || 30th August 2023 || Regulatory reports |

This report provides detailed analysis around the current regulatory framework in place on a federal level in the US for hemp, CBD, other cannabinoids as well medical and recreational cannabis ...

Has a wording error in a new law just banned hemp in Arkansas?

Written by Anthony Traurig || 20th April 2023 || News analysis |

Arkansas may have inadvertently banned hemp with the passage of a bill that was intended to prohibit the production and sale of intoxicating hemp-derived cannabinoid products but went much further ...

An overview of intoxicating hemp-derived cannabinoids in Europe

Written by Anthony Traurig || 2nd January 2023 || Regulatory reports |

This report examines the basic regulatory framework for the most popular IHDC product categories and identifies the IHDC product that is most likely to be allowed in Europe ...

The question of semi-synthetics – HHC comes under scrutiny by EU authorities

Written by Anthony Traurig || 29th December 2022 || News analysis |

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has begun the process of collecting data and evaluating the risk posed by hexahydrocannabinol (HHC) and other semi-synthetic cannabinoids ...

What the cannabis scheduling review means for the US

Written by Anthony Traurig || 21st October 2022 || Regulatory reports |

US president Joe Biden has called for a scheduling review of cannabis. This report will examine the procedure, potential outcomes, and implications of this scheduling...

Which US states allow the sale of intoxicating hemp-derived cannabinoids in dispensaries?

Written by Anthony Traurig || 16th August 2022 || Regulatory reports |

This report examines which US states allow the sale of intoxicating hemp-derived cannabinoid (IHDC) products in licensed dispensaries and which states have dispensaries offering them – regardless of whether they are permitted – to demonstrate the states that...

US regulatory trends on intoxicating hemp-derived cannabinoids

Written by Anthony Traurig || 21st June 2022 || Regulatory reports |

Intoxicating hemp-derived cannabinoids (IHDC) have been major disruptors in the CBD and legal cannabis sectors in the US for some time now. This report details and analyses recent developments in their regulation ...

Mexico: CBD and cannabis regulation, May 2022

Written by Anthony Traurig || 27th May 2022 || Regulatory reports |

Mexico is set to become a major global market for cannabis and CBD, but its potential has been stymied by congressional inaction ...

Regulatory report: US state-by-state taxation of medical cannabis

Written by Anthony Traurig || 8th March 2022 || Regulatory reports |

This report covers, state by state, the widely differing tax policies for medical cannabis in the US ...

Virginia bill could pose significant threat to CBD products in the state

Written by Anthony Traurig || 3rd March 2022 || News analysis |

A bill originally aimed at restricting the shapes that edible cannabis products may take has morphed into a potential significant threat to CBD products in Virginia ...

Regulatory report: Hemp products under California’s Assembly Bill 45

Written by Anthony Traurig || 3rd February 2022 || Regulatory reports |

This report offers a comprehensive overview of California's Assembly Bill (AB) 45, which is the culmination of years of legislative attempts to regulate hemp-derived products in the state ...

More of the same in US 2022 – expect state moves and federal stalemate

Written by Anthony Traurig || 17th January 2022 || News analysis |

Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though we anticipate some continued movement at state level ...

Intoxicating hemp products in the US – opportunity or risk?

Written by Anthony Traurig || 20th December 2021 || Regulatory reports |

Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law ...

US states fall over themselves backwards to sow further confusion over delta-8

Written by Anthony Traurig || 21st October 2021 || Blogs , News analysis |

A few US states may have over-corrected course in their rushing to modify regulations to cover hemp-derived delta-8 THC ...

Regulatory report: US state-by-state regulation of CBD vaping products

Written by Anthony Traurig || 25th August 2021 || Regulatory reports |

This report covers, state by state, the question of whether each US state allows the sale of hemp-derived CBD vaping products and on what legal terms ...

Regulatory report: US state-by-state regulation of CBD in pet food

Written by Anthony Traurig || 13th July 2021 || Regulatory reports |

This report examines US federal and all state law as it pertains to CBD in pet food ...

Regulatory report: US state-by-state regulation of dispensary sales

Written by Anthony Traurig || 31st May 2021 || Regulatory reports |

This report examines which US states that have legalised medical or recreational cannabis allow for the sale of hemp-derived CBD products in their dispensaries ...

Regulatory report: US state-by state regulation of delta-8 THC

Written by Anthony Traurig || 21st May 2021 || Regulatory reports |

Because US states can and do differ from federal law when it comes to controlled substances, it is important to analyse each state's law on delta-8 THC. This report provides a state-by-state guide to delta-8 THC ...

Regulatory report: US – importing and exporting hemp and CBD products

Written by Anthony Traurig || 1st March 2021 || Regulatory reports |

This report examines the legal requirements and practical considerations when importing to and exporting from the largest CBD market in the world – the US ...

Is this the year? US cannabis and CBD law reform efforts worth watching in 2021

Written by Anthony Traurig || 11th February 2021 || News analysis |

The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers ...

Regulatory report: interstate shipping of CBD and hemp in the US

Written by Anthony Traurig || 25th January 2021 || Regulatory reports |

This report examines the current rules for US interstate transportation, covering documentation needed as well as individual courier rules ...

A brighter year ahead on cannabis rules? Our 2021 predictions for US regulation

Written by Anthony Traurig || 13th January 2021 || News analysis |

CBD-Intel presents some predictions of what regulatory moves could take place around cannabis, hemp and CBD in the US in 2021 ...

State officials on both sides as South Dakota goes to court over legalisation

Written by Anthony Traurig || 5th January 2021 || News analysis |

South Dakota’s governor has put public cash behind a legal challenge to a move – backed by a majority of voters – to legalise recreational cannabis in the US state. But can the lawsuit overturn the vote? ...

The long wait goes on for a successful European novel food application

Written by Anthony Traurig || 28th December 2020 || News analysis |

Officials from the European Commission (EC) met with CBD-Intel to discuss the status of novel food applications in light of the ruling in the Kanavape case ...

Regulatory report: the implications of the Kanavape case on CBD in the EU

Written by Anthony Traurig || 14th December 2020 || Regulatory reports |

The implications of the Kanavape ruling could be far-reaching. This report examines the decision by the Court of Justice of the European Union (CJEU) and some of its likely consequences ...

LATEST ALERTS

Written by Anthony Traurig || 8th October 2024 || Market data , Regulatory databases |

Written by Anthony Traurig || 26th July 2024 || Regulatory databases |

Written by Anthony Traurig || 26th July 2024 || Regulatory databases |

Written by Anthony Traurig || 25th July 2024 || Market reports , Regulatory reports |

Written by Anthony Traurig || 17th June 2024 || Regulatory databases |

Written by Anthony Traurig || 4th October 2023 || Regulatory reports |

Written by Anthony Traurig || 1st September 2023 || News analysis |

Written by Anthony Traurig || 30th August 2023 || Regulatory reports |

Written by Anthony Traurig || 20th April 2023 || News analysis |

Written by Anthony Traurig || 2nd January 2023 || Regulatory reports |

Written by Anthony Traurig || 29th December 2022 || News analysis |

Written by Anthony Traurig || 21st October 2022 || Regulatory reports |

Written by Anthony Traurig || 16th August 2022 || Regulatory reports |

Written by Anthony Traurig || 21st June 2022 || Regulatory reports |

Written by Anthony Traurig || 27th May 2022 || Regulatory reports |

Written by Anthony Traurig || 8th March 2022 || Regulatory reports |

Written by Anthony Traurig || 3rd March 2022 || News analysis |

Written by Anthony Traurig || 3rd February 2022 || Regulatory reports |

Written by Anthony Traurig || 17th January 2022 || News analysis |

Written by Anthony Traurig || 20th December 2021 || Regulatory reports |

Written by Anthony Traurig || 21st October 2021 || Blogs , News analysis |

Written by Anthony Traurig || 25th August 2021 || Regulatory reports |

Written by Anthony Traurig || 13th July 2021 || Regulatory reports |

Written by Anthony Traurig || 31st May 2021 || Regulatory reports |

Written by Anthony Traurig || 21st May 2021 || Regulatory reports |

Written by Anthony Traurig || 1st March 2021 || Regulatory reports |

Written by Anthony Traurig || 11th February 2021 || News analysis |

Written by Anthony Traurig || 25th January 2021 || Regulatory reports |

Written by Anthony Traurig || 13th January 2021 || News analysis |

Written by Anthony Traurig || 5th January 2021 || News analysis |

Written by Anthony Traurig || 28th December 2020 || News analysis |

Written by Anthony Traurig || 14th December 2020 || Regulatory reports |

Sign up to our newsletter

Start your FREE trial